Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409873 · ClinicalTrials.gov registry record · Phase 2
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04409873 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 54 participants.
The verdict
NCT04409873, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest Pro-Health Multi-Protection (Crest, USA), or Listerine Zero (Johnson and Johnson, USA). Study participants will be asked to rinse/gargle with 10-20ml (according to the rinse instructions) of the assigned solutions 4 times per day, for 30-60 seconds, for 4 weeks.
Interventions
- DRUG Oral-B Mouth Sore mouthwash
- DRUG Crest Pro-Health Multi-Protection mouthwash
- DRUG CloSYS Ultra Sensitive Rinse mouthwash
- DRUG Distilled water
- DRUG Listerine Zero Mouthwash Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2022-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409873
The ClinicalTrials.gov registry entry for NCT04409873 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oral-B Mouth Sore mouthwash is the first listed.
NCT04409873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04409873 about?
NCT04409873 is a clinical study titled "Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)". In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest Pro-Health Multi-Protection (Crest, USA), or Listerine Zero (Johnson and Johnson...
What is the current status of trial NCT04409873?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2021-03-31. Estimated completion is 2022-09-10.
What interventions are being tested in trial NCT04409873?
The interventions under investigation include: Oral-B Mouth Sore mouthwash (DRUG), Crest Pro-Health Multi-Protection mouthwash (DRUG), CloSYS Ultra Sensitive Rinse mouthwash (DRUG), Distilled water (DRUG), Listerine Zero Mouthwash Product (DRUG).
Who is sponsoring clinical trial NCT04409873?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.